Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ESH MM 2018 | Treatment sequencing in multiple myeloma: a multitude of options

Heinz Ludwig • 5 Oct 2018
ESH MM 2018
Multiple Myeloma Bortezomib Daratumumab Dexamethasone Elotuzumab Lenalidomide Pomalidomide

Heinz Ludwig, MD, PhD, from Wilhelminen Cancer Research Institute, Vienna, Austria, discusses treatment sequencing in multiple myeloma (MM). Dr Ludwig covers the many options available to treat MM, particularly when options are restricted in cases of drug resistance and relapse. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Heinz Ludwig

Identifying high-risk multiple myeloma & improving treatment strategies in this patient population
Heinz Ludwig et al. • 15 Sep 2022
Factors affecting renal response in myeloma with acute renal failure due to cast nephropathy 5:06
Factors affecting renal response in myeloma with acute renal failure due to cast nephropathy
Heinz Ludwig • 20 Nov 2024
The changing approach to infection management with the influx of novel immunotherapies in myeloma 5:44
The changing approach to infection management with the influx of novel immunotherapies in myeloma
Heinz Ludwig • 20 Nov 2024
The complexities of selecting patients with smoldering myeloma for therapeutic intervention 4:35
The complexities of selecting patients with smoldering myeloma for therapeutic intervention
Heinz Ludwig • 20 Nov 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals